Business
WuXi Biologics Achieves "CDMO of the Year" Among Three Prestigious IMAPAC Awards
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025 hosted by IMAPAC. Since 2017, WuXi Biologics has received multiple awards in various categories at IMAPAC's events.
About this update from Wuxi Biologics (cayman) Inc.
[{"type":"text","content":"SINGAPORE, Sept. 11, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced that it has received the "CDMO of the Year – Asia Pacific", "Best Biologics CDMO Award: Bioprocessing", and "Best Biologics CDMO in Greater China Region" at the Asia Pacific Biologics CDMO Excellence Awards (APBCEA) 2025 hosted by IMAPAC. Since 2017, WuXi Biologics has received multiple awards in various categories at IMAPAC's events.","length":542,"tagName":"p"},{"type":"text","content":"APBCEA aims to celebrate the outstanding contributions of leading CDMO that are accelerating biologics innovation across Asia Pacific. This award recognizes excellence in biomanufacturing, cutting-edge R&D, technological innovation, and strategic partnerships that drive the development and commercialization of novel biologic therapies.","length":346,"tagName":"p"},{"type":"text","content":"WuXi Biologics is committed to advancing integrated technology platforms to accelerate the discovery, development, and manufacturing of biologics. It boasts one of the industry's largest portfolios of complex biologics, with total integrated projects reaching 864, including 168 bispecific and multispecific antibodies and 225 ADCs. The development cycle for its monoclonal antibody projects, from DNA to Investigational New Drug (IND) application, has been shortened to 6 months, demonstrating high flexibility. Behind these milestone achievements lies the solid support of the company's world-class quality systems—which have achieved a 100% success rate in Pre-License Inspections (PLI) and passed 44 inspections by global regulatory authorities, including 22 conducted by the FDA and EMA. Leveraging these innovative technologies, world-class quality systems, an extensive global manufacturing network, and a proven track record of high success rates, WuXi Biologics provides end-to-end services for over 1000 clients worldwide, advancing their biologics into the clinic and on to the market.","length":1104,"tagName":"p"},{"type":"text","content":"Dr. Chris Chen, CEO of WuXi Biologics, commented, "We are very pleased that WuXi Biologics has once again won multiple awards presented by IMAPAC, which fully demonstrates the recognition we have earned f...